- Approved
- Type
- Therapeutic biologic · Injection
- FDA-approved use
- To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatmentWording from FDA's list of novel approvals.
- FDA review
- Priority reviewOrphan drug
- Company
- Scholar Rock
- Application
- BLA 761463
- Specialty
- Neurology
At a glance
Isembyld (apitegromab-mstn) is a monoclonal antibody approved on September 11, 2026 for spinal muscular atrophy (SMA) in adults and children 2 years and older who are already receiving an SMN2-targeted treatment. In the pivotal trial, children aged 2 to 12 years on the approved dose gained 2.2 more points on the HFMSE motor scale at 1 year than those on placebo (95% CI 0.49 to 3.95; nominal P=0.0121). The main safety point is a risk of fractures, including serious ones; there is no boxed warning.
What it is and how it works
Isembyld is a fully human IgG4 antibody that binds promyostatin and latent myostatin. This blocks activation of myostatin and its signaling. Existing SMA drugs raise SMN protein levels or replace the SMN1 gene. Isembyld acts on muscle instead and is used on top of an SMN2-targeted drug, not in place of one.
Pivotal trials
SAPPHIRE (Study 1) NCT05156320
- Design
- Phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Treatment was given by intravenous infusion every 4 weeks for about 1 year. Children aged 2 to 12 years were randomized 1:1:1 to two apitegromab doses or placebo. Participants aged 13 to 21 years were randomized 2:1 to the higher dose or placebo.
- Patients
- 188 patients aged 2 to 21 years with 5q SMA, all nonambulatory and all on nusinersen or risdiplam. The main efficacy group was 156 patients aged 2 to 12 years. In the label analysis, 53 received the approved dose and 50 received placebo.
- Compared with
- Placebo
- Primary endpoint
- Change from baseline in HFMSE total score at 1 year in patients aged 2 to 12 years.
Result
On the approved dose, the label reports an HFMSE change of 1.0 versus -1.2 with placebo. The difference was 2.2 points (95% CI 0.49 to 3.95; nominal P=0.0121). The publication, which pooled both doses, reported a difference of 1.8 points (95% CI 0.30 to 3.32; P=0.019). The higher dose alone did not differ significantly from placebo (1.4 points; 95% CI -0.34 to 3.13; P=0.11).
- Other results
- A change in HFMSE of 3 points or more at 1 year occurred in 34.2% on the approved dose versus 13.5% on placebo (odds ratio 3.8; 95% CI 1.33 to 10.90; nominal P=0.0125). Results in patients aged 13 to 21 years on the higher dose showed a consistent trend. The effect was similar across predefined subgroups.
- Safety in the trial
- Adverse event rates and severity were similar to placebo in the publication, and no patient stopped treatment because of an adverse event. Fractures occurred in 5 of 53 patients on the approved dose, 3 of 53 on the higher dose, and 1 patient on placebo. No patient stopped treatment for a fracture.
EvidencePulse™
Ask about Isembyld
The question that opens in EvidencePulse
How does Isembyld (apitegromab-mstn) compare with the alternatives (Nusinersen, Risdiplam, Onasemnogene abeparvovec) for spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment? Summarize head-to-head and indirect evidence, efficacy, safety and where each fits, with citations.
Ask in EvidencePulseFree to try, more with 2MM+.
Deep research is a core feature of 2MM Max.
Safety signals
There is no boxed warning. The label warns of fractures, including serious ones. Most patients with fractures had low bone density, earlier fractures, or contractures, and some fractures had no clear cause such as a fall. Femur fractures occurred in three treated patients in the pivotal trial, and the label advises caution in patients with low bone density or multiple fractures and a review of risks and benefits after any fracture. The most common adverse reactions were upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, pharyngitis, and hypersensitivity.
What it competes with
SMA is treated with drugs that increase SMN protein or replace the SMN1 gene, along with supportive care. Isembyld is the only drug here that targets muscle, and it is given alongside an SMN2-targeted drug.
- NusinersenIntrathecal antisense drug that changes SMN2 splicing to raise SMN protein. It is the background therapy in the pivotal trial.
- RisdiplamOral SMN2 splicing modifier. It is the other background therapy allowed in the pivotal trial.
- Onasemnogene abeparvovecGene replacement therapy that delivers a working SMN1 gene. It is used mainly in young children.
- Supportive careRespiratory, nutritional, orthopedic, and rehabilitation care remain part of management for all patients.
Bottom line for clinicians
Isembyld is for patients with SMA aged 2 years and older who are already on nusinersen or risdiplam and still have motor deficits. The motor gain was modest and the primary P value is described as nominal. Weigh this against the fracture risk, especially in patients with low bone density, prior fractures, or contractures.
Our coverage
We have not covered this drug yet.
Sources
- FDA approval letter
- Full prescribing information (FDA)
- Current label on DailyMed
- FDA review documents
- FDA list of novel approvals
- Crawford TO, et al. Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2025;24:727-739.
- ClinicalTrials.gov NCT05156320
Dosing, contraindications and full warnings are in the prescribing information.
New FDA approvals in your inbox
The free 2 Minute Medicine Daily Brief: new approvals, landmark trials and the day's top studies, written by physicians.
Your subscription opens securely in a new tab.
Last updated October 29, 2026 by 2 Minute Medicine.
For healthcare professionals. A summary of public FDA documents and published trials, not medical advice. Check the full prescribing information before prescribing.